PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 2013JNCI Journal of the National Cancer Institute223 citations

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

View Full Paper
IŠIvana ŠestakMDMitch DowsettLZLila Zabaglo

Key Points

Key points are not available for this paper at this time.

Abstract

None of the IHC4 markers provided statistically significant prognostic information in years 5 to 10, except for nodal status and tumor size. ROR gave the strongest prognostic information in years 5 to 10. These results may help select patients who could benefit most from hormonal therapy beyond 5 years of treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Šestak et al. (2013) studied this question.

synapsesocial.com/papers/69d7af6eb1cb92dd1bb8bb28https://doi.org/10.1093/jnci/djt244
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Annual hazard rates of recurrence for breast cancer after primary therapy.1996 · 837 citations
  2. 2Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial2008 · 466 citations
  3. 3Abstract S1-9: Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study2012 · 18 citations
  4. 4Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials2011 · 3,099 citations
  5. 5Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.1998 · 904 citations